Figure 1
Figure 1. Cytotoxic effect of ABT-737 in cell lines of hematologic malignanices. (A) IC50 values (mM) to ABT-737. HBL2 cell line was the most sensitive through all time points explored; confidence intervals are shown between parenthesis. (B) Model of in vitro exposure to ABT-737 and other drugs is shown on the upper left. Percentage of cells killed compared to control for each treatment group (± SD) is shown as histograms. All drug concentrations used approximated the IC10-25. (C) Multiple comparison analysis for ABT-737 at 100 nM in combination with other drugs at 10 nM in RL (DLBCL). Probability values for all averages comparisons proved (P values). Where statistically significant (ie, P .05), bolded cohorts are superior. A = ABT-737, D = doxorubicin, E = etoposide, P = pralatrexate, R = rituximab, B = bortezomib.

Cytotoxic effect of ABT-737 in cell lines of hematologic malignanices. (A) IC50 values (mM) to ABT-737. HBL2 cell line was the most sensitive through all time points explored; confidence intervals are shown between parenthesis. (B) Model of in vitro exposure to ABT-737 and other drugs is shown on the upper left. Percentage of cells killed compared to control for each treatment group (± SD) is shown as histograms. All drug concentrations used approximated the IC10-25. (C) Multiple comparison analysis for ABT-737 at 100 nM in combination with other drugs at 10 nM in RL (DLBCL). Probability values for all averages comparisons proved (P values). Where statistically significant (ie, P .05), bolded cohorts are superior. A = ABT-737, D = doxorubicin, E = etoposide, P = pralatrexate, R = rituximab, B = bortezomib.

Close Modal

or Create an Account

Close Modal
Close Modal